ArticleJournal of clinical and experimental hepatology
Post-COVID-19 Cholestasis: A Case Series and Review of Literature.
Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Secondary Sclerosing Cholangitis (SSC): An Underrecognized Complication of Severe COVID-19 Pneumonitis.Cureus · 2024Article
- Article
- Post-COVID-19 Cholangiopathy: Clinical and Radiologic Findings.Korean journal of radiology · 2023Article
- Histopathological Features Predicting Long-term Clinical Outcomes in Patients with Vanishing Bile Duct Syndrome.Journal of clinical and translational hepatology · 2023Article
- Post-COVID-19 cholangiopathy: Systematic review.World journal of methodology · 2023Article
- Post-COVID-19 cholangiopathy: Current understanding and management options.World journal of gastrointestinal surgery · 2023Review
- Investigating the Impact of COVID-19 Vaccines on Liver Function: Insights From a Single-Institute Study.Cureus · 2023Article
- Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients.Biomolecules · 2023Review
- Outcomes in Patients with Liver Dysfunction Post SARS-CoV-2 Infection: What Should We Measure?Hepatic medicine : evidence and research · 2023Review
- Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure.Frontiers in medicine · 2023Review
- Secondary Sclerosing Cholangitis After SARS-CoV2: ICU Ketamine Use or Virus-Specific Biliary Tropism and Injury in the Context of Biliary Ischemia in Critically Ill Patients?Hepatic medicine : evidence and research · 2023Article
- COVID-19-Associated Liver Injury.Hepatic medicine : evidence and research · 2023Review
- Treatment of Acquired von Willebrand Disease due to Extracorporeal Membrane Oxygenation in a Pediatric COVID-19 Patient with Vonicog Alfa: A Case Report and Literature Review.TH open : companion journal to thrombosis and haemostasis · 2023Article
- COVID-Associated Cast-Forming Cholangiopathy: A Commentary on Disease Mechanism, Treatment, and Prognosis.Hepatic medicine : evidence and research · 2023Article
- Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients.Vaccine · 2022Article
- Liver Transplantation: Protocol for Recipient Selection, Evaluation, and Assessment.Journal of clinical and experimental hepatologyReview
- COVID-related Vanishing Bile Duct Syndrome (VBDS).Journal of clinical and experimental hepatologyArticle
- Post-COVID-19 Cholangiopathy: A Systematic Review.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronavirus disease-2019 (COVID-19) cholangiopathy is a recently known entity. There are very few reports of liver transplantation (LT) for COVID-19-induced cholangiopathy. It is well known that vaccines can prevent severe disease and improve outcomes. However, there are no reports on the impact of COVID-19 vaccines on cholestasis. Therefore, we aimed to compare the course and outcome of patients who developed cholestasis following COVID-19 infection among vaccinated and unvaccinated individuals. Results: Eight unvaccinated and seven vaccinated individuals developed cholestasis following COVID-19 infection. Baseline demographics, presentation, severity, and management of COVID-19 were similar in both groups. However, patients in the unvaccinated group had a protracted course. The peak ALP was 312 (239-517) U/L in the vaccinated group and 571.5 (368-1058) U/L in the unvaccinated group ( Conclusion: Post-COVID-19 cholestasis is associated with high morbidity and mortality, meriting early identification and appropriate management. Vaccination can modify the course of severe COVID-19 infection and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.